Roivant Sciences, a biotech company started by Republican presidential candidate Vivek Ramaswamy, is in talks to sell an experimental drug for a debilitating stomach disease to Roche Holding, in a deal that could be valued at more than $7 billion.
Sale of the drug, for conditions known as ulcerative colitis and Crohn’s disease, could be announced in the coming days, according to people familiar with the matter. The talks could still fall apart and another suitor could swoop in, one of the people cautioned.
Roivant, started in 2014 by Ramaswamy, has focused on acquiring drugs stalled in development. It creates subsidiaries to develop and commercialize them.
Read the full story on The Wall Street Journal here.